NCT04688606Unknown不适用
Zhongnan Hospital of Wuhan University
Zhongnan Hospital1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2020年1月22日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- Clinical detection of circulating tumor cells
研究概览
简要总结
Through the screening of CTCs in patients with suspected liver cancer and liver tumor resection or liver transplantation, the number of CTCs in the blood of liver cancer patients before and after surgery is monitored, and the clinical application significance of CTCs in liver cancer screening and postoperative recurrence monitoring in liver cancer patients is evaluated.
详细描述
- Screen patients with suspected liver cancer Long-term exposure to liver cancer risk factors (hepatitis B carriers, past history of schistosomiasis, long-term diet of Aspergillus food, history of liver cirrhosis, etc.), patients with liver cancer are initially suspected.
- Monitor the number of CTCs in the blood of patients with liver cancer before and after surgery Imaging examinations show that liver space is occupied by patients with suspected liver cancer. Use CTCBIOPSY® technology to monitor patients' surgical operations (including interventional therapy, tumor resection, or liver cancer liver transplantation) at different times 1-3 days before, 1 month after surgery, and 6 months after surgery The number of CTCs in peripheral blood.
- To evaluate the clinical application significance of CTCs in liver cancer screening and postoperative recurrence monitoring in patients with liver cancer Combined with clinicopathology, tumor marker examination and imaging examination, clinical follow-up and follow-up, analyze the clinical significance of CTCs detection in liver cancer patients, and focus on evaluating the relationship between circulating tumor cells in liver cancer screening and postoperative recurrence, and establish a new The liver cancer prediction model improves the prognosis of liver cancer patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Primary diagnosis of suspected hepatocellular carcinoma; or liver cancer patients who have undergone liver transplantation, radical resection or ablation of liver cancer;
- •Age 18-75 years old;
- •ASA (risk of anesthesia) score I-II;
- •The ECOG score is 0-1;
排除标准
- •In addition to hepatocellular carcinoma, patients diagnosed with other types of tumors;
- •Patients with extrahepatic or lymphatic metastasis;
- •Patients who still have serious complications 4 weeks after surgery;
- •Patients who cannot provide informed consent;
结局指标
主要结局
Clinical detection of circulating tumor cells
时间窗: 2020.01.20-2021.02.28
To evaluate the specificity of CTCs for liver cancer screening and the feasibility of early recurrence after interventional therapy, tumor resection or liver transplantation
次要结局
- Circulating tumor cell function detection and verification(2020.03.01-2021.05.20)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Prognostic Value of Liver Cancer CTCs Isolated by a Novel Microfluidic PlatformHepatocellular CarcinomaCirculating Tumor CellWhole Genome SequencingNCT05242237The Second Affiliated Hospital of Chongqing Medical University300
Unknown
不适用
Circulating Tumor Cells for Hepatocellular CarcinomaCarcinoma, HepatocellularNeoplasm Circulating CellsNCT01930383National Taiwan University Hospital150
已完成
3 期
Screening of Hepatocellular Carcinoma in Patients With Compensated CirrhosisCompensated CirrhosisNCT00190385Assistance Publique - Hôpitaux de Paris1,200
招募中
2 期
Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol EmulsionCarcinoma, HepatocellularNCT03727633University Hospital, Montpellier53
Unknown
2 期
Randomized Control Trial (RCT) of Transarterial Chemoembolization (TACE) Versus TACE and Oral Drug Therapy in the Treatment of Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaNCT00522405All India Institute of Medical Sciences, New Delhi